Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.
This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
HER2/HER3 in Lung Cancer
Genomic studies have identified human epidermal growth factor receptor 2 (HER2) as the main oncogenic driving force behind some types of particularly aggressive metastatic cancers: breast cancer (BC), gastrointestinal cancers (particularly gastric/gastroesophageal junction [GC/GEJ], colorectal [CRC]), and even non-small cell lung cancer (NSCLC). HER2 appears to work in tandem with epidermal growth factor receptor (EGFR) family members, including the recently discovered HER3, in aggressive tumors with a poorer prognosis characterized frequently by treatment resistance. Fortunately, newly approved HER2-targeted treatment options work through varying mechanisms of action that may be able to obviate treatment resistance observed in older HER2-targeted pharmacologic agents. New and emerging treatments that target HER2 and HER3 may soon change standard of care for some types of HER2-driven cancers and will provide more highly personalized therapeutic options for patients with these types of metastatic cancer. This program will provide education on the prevalence of and outcomes in various cancers with HER2 alterations, HER2 testing recommendations, the role of HER3 in treatment resistance. This program will provide education on new and emerging treatment options for patients with HER2-altered lung cancer.
Michael Pishvaian, MD, PhD
Department of Oncology
Director of GI, Developmental Therapeutics, and Clinical Research Programs
John Hopkins Kimmel Cancer Center
Estelamari Rodriguez, MD
Assistant Professor of Clinical Medicine
Department of Medical Oncology
Sylvester Comprehensive Cancer Center
University of Miami
This educational activity has been designed to meet the needs of medical oncologists, pathologists, radiation oncologists, surgical oncologists and advanced practice providers (APPs) involved in the management of patients with solid tumors.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of February 1, 2022 through February 1, 2023, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Tumor Board Tuesday. Integrity Continuing Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this other activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
Michael Pishvaian, MD, PhD
Consultant/Advisory Committees: AstraZeneca, Foundation Medicine, Merck
Ownership Interest: Perthera, Inc.
Funding to Institution: Arcus, Merck, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Estelamari Rodriguez, MD
Consultant: AstraZeneca, Bristol Meyers Squibb, Eli Lilly, Genentech, Janssen Oncology
Speaker: Research to Practice, Targeted Oncology
The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.